Research Profile
Dr. Richie is a leading expert in the diagnosis and treatment of prostate cancer. Chief of Urology at Brigham and Women's Hospital, he is the Elliott Carr Cutler Professor of Surgery at Harvard Medical School and Chairman of the Harvard Program in Urology (Longwood area). Dr. Richie is a past president of the Society of Urologic Oncology, Society of University Urologists and the American Board of Urology. He has served on the National Cancer Advisory Board and the National Cancer Center Network Advisory Board/Panel.
Dr. Richie's major research interests include testicular cancer, prostate cancer, and urology related malignancies
Back to the top
Projects
Back to the top
Funding
Back to the top
Selected Publications
(from a total of 380 peer-reviewed articles)
For the latest articles by Dr. Jerome Richie, please visit
.
Richie JP. Testis cancer: the cost of progress. J. Urol. 153:986, 1995.
Richie JP. Genitourinary Tract: procedures for diagnosis, biopsy and endoscopy. In: MacDonald JS, Haller DG, Mayer RJ, (Eds). Oncologic Therapeutics. Philadelphia: J. B. Lippencott Co, pp. 27-9, 1995.
Garnick MB and Richie JP: Renal Neoplasia. In Brenner BM (Ed.): The Kidney. 5th Edition. Philadelphia: W.B. Saunders Co. p. 1959-77, 1995.
Comiter CV, Capelouto CC, Tobin MS, Dluhy RG, and Richie JP. Glucocorticoid remediable aldosteronism: a rare hereditary form of adrenocorticotropic hormone regulated mineralocorticoid hypertension. J Urol 154:510-2, 1995.
Richie JP. Discussion session: clinical data on the role of bicalutamide in metastatic prostate cancer. Urology 47:80-84, 1996.
Lu ML, Sato M, Cao B, Richie JP. UV irradiation induced apoptosis leads to activation of a 36-kDa myelin basic protein kinase in HL-60 cells. Proc Natl Acad Sci USA 93:8977-82, 1996.
Richie JP. New aspects of surgery and urinary diversion. Advances in Oncology 12:25-29, 1996.
Richie JP. Testicular cancer: what staging investigations are indicated? Sem. Urol. Onc. 14:13-16, 1996.
Richie JP, Stolbach L, Atkins MB. "Cancer of the Kidney." In: American Cancer Society (eds): Cancer Manual, 9th Edition, pp. 434-445, 1996.
Raghavan D, Shipley WU, Hall RR, Richie JP. Biology and management of invasive bladder cancer. In: Raghavan D, Scher HI, Leibel LA, Lange P (eds): Principles and Practices of Genitourinary Oncology, Lippincott Raven, Philadelphia, 281-299, 1996.
Watson DW, Kantoff PW, Richie JP: Testis Cancer: Staging and Imaging. In Vogelzang, Scardino, Shipley, Coffey (Eds). The Comprehensive Textbook of Genito-Urinary Oncology , Williams and Wilkins, Baltimore, pg. 981-91, 1996.
Hutcheson JC, Richie JP. Intrascrotal Masses and Tumors. In: Conn RB, Borer WZ, Snyder JW (eds). Current Diagnosis, W.B. Saunders Company, Philadelphia, 1996.
Olumi AF, Garnick MB, Renshaw AA, Benson CA, Richie JP. Leydig cell hyperplasia mimicking testicular neoplasm. Urology 48:647-9, 1996.
Lu ML, Sato M, Cao B, Richie JP. Myelin basic protein kinase in HL-60 cells. Proc Natl Acad Sci USA 93:8977-82, 1996.
D'Amico AV, Chang H, Holupka E, Renshaw AA, Desjarden A, Chen M, Loughlin KR, Richie J. Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. Urology 49:385-91, 1997.
Richie JP. Localized prostate cancer: overview of surgical management. Urology 49:35-7, 1997.
Richie JP, Murphy GP, Walther P. Prostate cancer surgical practice guidelines. Society of surgical oncology practice guidelines: prostate cancer. Oncology 11:907-12, 1997.
Richie JP, Kantoff PW, Shapiro CL. Renal cell carcinoma. In: Holland JF, Bast RC, Morton DL, Frei E, Kufe DW, Weichselbaum RR (eds): Cancer Medicine, 4th Edition, Williams and Wilkins, Baltimore, pg. 2085-2096, 1997.
Richie JP and Kantoff PW. Neoplasms of the renal pelvis and ureter. In: Holland JF, Bast RC, Morton DL, Frei E, Kufe DW, Weichselbaum RR (eds): Cancer Medicine, 4th Edition, Williams and Wilkins, Baltimore, pg. 2097-2103, 1997.
Loughlin KR, Richie JP. Prostate cancer after exogenous testosterone treatment for Impotence. J Urol 157:1845, 1997.
Steele GS, Richie JP. Current role of retroperitoneal lymph node dissection in testicular cancer. Oncology 11: 717-29, 1997.
Richie JP. Delayed Androgen Deprivation for Stage D1 Prostate Cancer. Urology 50:838-9, 1998.
D'Amico AV, Desjardin A, Chung A, Chen MH, Schultz D, Whittington R, Malkowicz SB, Wein A, Tomaszewski JE, Renshaw AA, Loughlin K, Richie JP. Assessment of outcome prediction models for pateints with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. Cancer 82:1887-96, 1998.
Richie JP. Screening for prostate cancer: why the controversy? Contemp Urol 10:26-37,1998.
Steele GS, Richie JP. Avoiding positive margins in prostate cancer surgery. Contemp Urol 10:74-88, 1998.
Renshaw AA, Santis WF, Richie, JP. Clinicopathological characteristics of prostate adenocarcinoma in men with atypical prostate needle biopsies. J Urol 159:2018-21, 1998.
Richie JP. Clinical stage I testicular cancer: the role of modified retroperitoneal lymphadenectomy. In: Hinman (ed), Atlas of Urologic Surgery, Second Edition, W. B. Saunders, Philadelphia, 1998.
Richie JP. Commentary on Thoracoabdominal Incision. In: Hinman F (ed): Atlas of Urologic Surgery, Second Edition, W.B. Saunders Company, Philadelphia, pp.890-5, 1998.
Richie JP. Urothelial Neoplasia of the Upper Urinary Tract. In: Whitfield HN, Hendry WF, Kirby RS, Duckett JW (eds): Textbook of Genitourinary Surgery Volume 2, Blackwell Science Ltd Publishers, pp.1159-65, 1998.
D’Amico AV, Desjardin A, Chen MH, Paik S, Schultz D, Renshaw AA, Loughlin KR, Richie JP. Analyzing outcome-based staging for clinically localized adenocarcinoma of the prostate. Cancer 83:2172-80, 1998.
Duque JL, Loughlin KR, O’Leary MP, Kumar S, Richie JP. Partial nephrectomy: alternative treatment for selected patients with renal cell carcinoma. Urology 52:584-90, 1998.
D’Amico AV, Davis A, Vargas SO, Renshaw AA, Jiroutek M, Richie JP. Defining the implant target volume for patients with low risk prostate cancer. Does the anterior base need to be treated? Int J Radiat Oncol Biol Phys 43: 587-90, 1999.
Richie JP. Urology. Journal of the American College of Surgeons 188:198-201, 1999.
Richie JR, Bono A, Denis LJ, Jewett MAS, Kakizoe T, Kotake T, Shirai T, Kate FJW. Tumor, nodes, metastasis (TNM) classification of bladder cancer. Urologic Oncology 4:90-93, 1999.
Renshaw AA, Richie JP. Subtypes of renal cell carcinoma. Different onset and sites of metastatic disease. Am J Clin Pathol 111: 539-43, 1999.
Richie JP, Olumi AF, Duque JL, D'amico AV. Stage Migration of T1c Prostate Cancer: Implications for Prognostic Nomograms. J Urol 161: 59, 1999.
Kerfoot BP, Steele GS, Datta MW, Richie JP. Carcinoid tumor in an ileal conduit diversion. J Urol 162:1685-6, 1999.
Richie JP: Anti-Androgens and Other Hormonal Therapy for Prostate Cancer. Urology 54:15-18, 1999.
Kumar SK, Duque JL, Guimaraes K, DiCanzio J, Loughlin KR, Richie JP. Short and Long-Term Morbidity of Thoracoabdominal Incision for Nephrectomy: A Comparison with the Flank Approach. J Urol 162:1927-1929, 1999.
Richie JP: Editorial: Testicular CIS: Who is at risk, and how should the problem be dealt with? Contemporary Urology 11:38-50, 1999.
D'Amico AV, Renshaw AA, Schultz D, Rocha S, Richie JP. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < 10 ng/ml and T1c, 2a: implications for patient selection for prostate-only therapy. Int J Radiat Oncol Biol Phys 45:847-51, 1999.
Dry SM, Hoffman MJ, Richie JP, Renshaw AA. Justification For the 1997 American Joint Committee on Cancer Staging System for Stage I Testicular Germ Cell Tumors. Laboratory Investigation 7: 94, 1999.
D'Amico AV, Renshaw AA, Arsenault L, Schultz D, Richie JP. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy. Int J Radiat Oncol Biol Phys 45:841-6, 1999.
D'Amico AV, Debruyne F, Huland H, Richie JP. Innovative treatment for clinically localized adenocarcinoma of the prostate: the future role of molecular imaging. Prostate 41:208-12, 1999.
Steele GS, Richie JP. Renal Angiomyolipoma: An Update. AUA News 5:22, 2000.
D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 3:259-64, 2000.
Steele GS, Richie JP. Management of Local Failure Following Treatment of Localized Prostate Cancer. In: Resnick MI, Thompson IM (eds): Advanced Therapy of Prostate Disease, B.C. Decker Inc. Publishers, pp. 365-377, 2000.
Steele GS, Kantoff PW, Richie JP. Staging and Imaging of Testis Cancer. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (eds): Staging and Imaging of Testis Cancer, Lippincott Williams & Wilkins Publishers, pp. 939-949, 2000.
Steele GS, Clancy TE, Datta MW, Weinstein M, Richie JP. Angiosarcoma arising in a testicular teratoma. J Urol 163:1872-3, 2000.
Steele GS, Richie JP. Management of low-stage nonseminomatous germ cell tumors of the testis. Comprehensive Therapy. 26:210-19, 2000.
D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. Molecular Urology 4:171-5, 2000.
D’Amico AV, Wu Y, Chen MH, Nash, M, Renshaw AA, Richie JP. Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a Gleason score = 7. Cancer 89:1810-7, 2000.
D’Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen MH, Hurwitz M, Kantoff PW, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Utilizing predictions of early prostate-specific antien failure to optimize patient selection for adjuvant systemic therapy trials. J Clin Oncol 18:3240-6, 2000.
D’Amico AV, Tempany CM, Cormack R, Hata N, Jinzaki M, Tunkali K, Weinstein M, Richie JP. Transperineal magnetic image guided prostate biopsy. J Urol 164:385-7, 2000.
D’Amico AV, Schultz D, Schneider L, Hurwitz M, Kantoff PW, Richie JP. Comparing prostate specific antigen outcomes after different types of radiotherapy management of clinically localized prostate cancer highlights the importance of controlling for established prognostic factors. J Urol 163: 1797-801, 2000.
D’Amcio AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18: 1164-72, 2000.
Richie JP. Urinary diversion: the patient’s choice. Annals of Surgical Oncology 7:1, 2000.
D’Amico AV, Whittington R, Malkowicz SB, Renshaw AA, Tomaszewski JE, Bentley C, Schultz D, Rocha S, Wein A, Richie JP. Estimating the impact on prostate cancer mortality of incorporating prostate-specific antigen testing into screening. Urology. 58:406-10 2001.
Liu BC, LaRose I, Weinstein LJ, Ahn M, Weinstein MH, Richie JP. Expression of telomerase subunits in normal and neoplastic prostate epithelial cells isolated by laser capture microdissection. Cancer. 92:1943-8, 2001.
Lu ML, Schneider MC, Zheng Y, Zhang X, Richie JP. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. Journal of Biological Chemistry 276: 13442-51, 2001.
D’Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer. J Urol 165: 126-9, 2001.
D'amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D, Rhude M, Rocha S, Wein A, Richie JP. Predicting Prostate Specific Antigen Outcome Preoperatively in the Prostate Specific Antigen Era. J Urol 166:2185-8, 2001.
Richie JP. Treating Testicular Cancer. Coping With Cancer 16:30-31, 2002.
D’Amico Av, Chen MH, Oh-Ung J, Renshaw AA, Cote K, Loffredo M, Richie JP. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radiat Oncol Biol Phys. 54:436-41, 2002.
Richie JP, O’Leary MP. By the way, doctor. Ultrasound treatment for Peyronie’s disease? I have Peyronie’s disease. Nothing seems to help. But I’ve heard about a new treatment that involves some kind of ultrasound. What do you think? Harv Health Lett. 27:8, 2002.
Richie JP. Editorial: testis cancer—paradigm for reduction in morbidity without sacrifice of efficacy. J Urol.168:1405, 2002
D'amico AV, Chen MH, Malkowicz SB, Whittington R, Renshaw AA, Tomaszewski JE, Samofalov Y, Wein A, Richie JP. Lower Prostate Specific Antigen Outcome Than Expected Following Radical Prostatectomy in Patients With High Grade Prostate And a Prostatic Specific Antigen Level of 4 Ng/Ml. or less. J Urol 167:2025-31, 2002.
D’Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95:281-6, 2002.
Richie, JP: A Plethora of Treatment Options. Infections in Urology 16-7, 2003.
D’Amico AV, Tempany CM, Schultz D, Cormack RA, Hurwitz M, Beard C, Albert M, Kooy H, Jolesz F, Richie JP. Comparing PSA Outcome after Radical Prostatectomy of Magnetic Resonance Imaging-Guided Partial Prostatic Irradiation in Select Patients with Clinically Localized Adenocarcinoma of the Prostate. Urology 62:1063-1067, 2003.
Steele GS, Kantoff PW, Richie JP: Staging and Imaging of Testis Cancer. In: Comprehensive Textbook of Genitourinary Oncolgy, 3rd Ed., [Vogelzang NJ, Scardino PT, Shipley WU, DeBruyne FMJ, Linehan WM (Eds.], Lipincott Williams and Wilkins, 2004.
Silverman SG, Tuncali K, Vansonnenberg E, Morrison PR, Shankar S, Ramaiya N, Richie JP. Renal Tumors: MR Imaging-guided Percutaneous Cryotherapy--Initial Experience in 23 Patients. Radiology. 2005 Aug;236(2):716-24.
Richie JP. Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. J Urol. 2005 Sep;174(3):931-2
McAleer SJ, Schultz D, Whittington R, Malkowicz SB, Renshaw A, Wein A, Richie JP, D'Amico AV. PSA outcome following radical prostatectomy for patients with localized prostate cancer stratified by prostatectomy findings and the preoperative PSA level. Urol Oncol. 2005 Sep-Oct;23(5):311-7.
Richie JP. Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. J Urol. 2005 Oct;174(4 Pt 1):1295.
Richie JP. Radical prostatectomy vs watchful waiting in early prostate cancer. BJU Int. 2005 Nov;96(7):951-2.
Richie JP. Urological oncology: testis cancer and advances in oncological therapy. J Urol. 2005 Dec;174(6):2224-5.
Dvorak T, Chen MH, Renshaw AA, Loffredo M, Richie JP, D'Amico AV. Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer. Urology. 2005 Nov;66(5):1024-8.
Richie JP. Increasing incidence of testicular germ cell tumors among black men in the United States McGlynn KA, Devesa SS, Graubard BI, Castle PE, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD. Urol Oncol. 2006 Mar-Apr;24(2):170.
Richie JP. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy Ronnen EA, Kondagunta GV, Bacik J, Marion S, Bajorin DF, Sheinfeld J, Bosl GJ, Motzer RJ, Department of Medicine, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY. Urol Oncol. 2006 Mar-Apr;24(2):170-1.
Richie JP. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice JD Jr, Dores GM, Gilbert ES, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD. Urol Oncol. 2006 Mar-Apr;24(2):171-2.
Richie JP. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial Mead GM, Cullen MH, Huddart R, Harper P, Rustin GJ, Cook PA, Stenning SP, Mason M, MRC Testicular Tumour Working Party, Medical Oncology Unit, Southampton General Hospital, Southampton, United Kingdom. Urol Oncol. 2006 Mar-Apr;24(2):172.
Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6315-20. Epub 2006 Apr 10.
Qin S, Qiu W, Ehrlich JR, Ferdinand AS, Richie JP, O'leary MP, Lee ML, Liu BC. Development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling. Proteomics. 2006 May;6(10):3199-209.
Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks J. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer. 2006 Jun;5(1):61-6.
Hurwitz MD, Schultz D, Richie JP, Wein AJ, Whittington R, Malkowicz SB, D'Amico AV. Radical prostatectomy for high-grade prostate cancer. Urology. 2006 Aug;68(2):367-70.
Rodrigues NA, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer. Cancer. 2006 Aug 1;107(3):514-20.
Richie JP. Urological survey: Urological oncology: testis cancer and advances in oncological therapy. J Urol. 2006 Sep;176(3):1000.
Montie JE, Abrahams NA, Bahnson RR, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG; National Comprehensive Cancer Network. Bladder cancer. Clinical guidelines in oncology. J Natl Compr Canc Netw. 2006 Nov;4(10):984-1014.
Mukhopadhyay NK, Ferdinand AS, Mukhopadhyay L, Cinar B, Lutchman M, Richie JP, Freeman MR, Liu BC. Unraveling androgen receptor interactomes by an array-based method: discovery of proto-oncoprotein c-Rel as a negative regulator of androgen receptor. Exp Cell Res. 2006 Nov 15;312(19):3782-95.
Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. 2006 Dec 1;107(11):2597-603.
Back to the top
Send Feedback to: 
